JP2024516825A5 - - Google Patents
Info
- Publication number
- JP2024516825A5 JP2024516825A5 JP2023566472A JP2023566472A JP2024516825A5 JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5 JP 2023566472 A JP2023566472 A JP 2023566472A JP 2023566472 A JP2023566472 A JP 2023566472A JP 2024516825 A5 JP2024516825 A5 JP 2024516825A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical product
- pharmaceutically acceptable
- acceptable salt
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181640P | 2021-04-29 | 2021-04-29 | |
| US63/181,640 | 2021-04-29 | ||
| PCT/US2022/071967 WO2022232808A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516825A JP2024516825A (ja) | 2024-04-17 |
| JP2024516825A5 true JP2024516825A5 (enExample) | 2025-05-09 |
Family
ID=81749580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566472A Pending JP2024516825A (ja) | 2021-04-29 | 2022-04-28 | トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226308A1 (enExample) |
| EP (1) | EP4329817A1 (enExample) |
| JP (1) | JP2024516825A (enExample) |
| KR (1) | KR20240019097A (enExample) |
| CN (1) | CN117897175A (enExample) |
| AU (1) | AU2022267389A1 (enExample) |
| CA (1) | CA3218253A1 (enExample) |
| CL (1) | CL2023003187A1 (enExample) |
| IL (1) | IL308052A (enExample) |
| MX (1) | MX2023012779A (enExample) |
| TW (1) | TW202308696A (enExample) |
| WO (1) | WO2022232808A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP4321168A3 (en) | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
-
2022
- 2022-04-28 CN CN202280044027.3A patent/CN117897175A/zh active Pending
- 2022-04-28 CA CA3218253A patent/CA3218253A1/en active Pending
- 2022-04-28 MX MX2023012779A patent/MX2023012779A/es unknown
- 2022-04-28 TW TW111116202A patent/TW202308696A/zh unknown
- 2022-04-28 AU AU2022267389A patent/AU2022267389A1/en active Pending
- 2022-04-28 EP EP22724607.1A patent/EP4329817A1/en active Pending
- 2022-04-28 IL IL308052A patent/IL308052A/en unknown
- 2022-04-28 JP JP2023566472A patent/JP2024516825A/ja active Pending
- 2022-04-28 US US18/288,650 patent/US20240226308A1/en active Pending
- 2022-04-28 WO PCT/US2022/071967 patent/WO2022232808A1/en not_active Ceased
- 2022-04-28 KR KR1020237040934A patent/KR20240019097A/ko active Pending
-
2023
- 2023-10-25 CL CL2023003187A patent/CL2023003187A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516825A5 (enExample) | ||
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| JP2021510725A5 (enExample) | ||
| JP2018528185A5 (enExample) | ||
| JP2002507571A (ja) | アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物 | |
| TW201914592A (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN117157106A (zh) | 药物在治疗肿瘤疾病中的应用 | |
| JP2008540364A5 (enExample) | ||
| Fukuoka et al. | Clinical studies of irinotecan alone and in combination with cisplatin | |
| JP2023546316A5 (enExample) | ||
| EP1711188B1 (en) | Anti-cancer therapies | |
| JP5881782B2 (ja) | 医薬組成物又は組合せ剤 | |
| CN105263499B (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| EP2117539B1 (en) | A method of administering an antitumor compound | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2023550043A5 (enExample) | ||
| AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| CN121001749A (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| CN107519171A (zh) | 洛匹那韦减轻伊立替康毒性的医药新用途 | |
| CN1774249A (zh) | 伊立替康在治疗耐受性乳腺癌中的应用 | |
| CN121127270A (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| HK1213475B (zh) | 用於癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| JP2023514742A5 (enExample) |